Myovant Sciences’ License Agreement with Accord Healthcare

Sidley represented Myovant Sciences on the deal. Pinsent Masons represented Accord Healthcare.

Myovant Sciences (NYSE: MYOV), a biopharmaceutical company focused on developing innovative treatments for women’s health and prostate cancer, announced an exclusive license agreement with Accord Healthcare, Ltd., to commercialize ORGOVYX® (relugolix, 120 mg) for the treatment of advanced, hormone-sensitive prostate cancer in the European Economic Area, United Kingdom, Switzerland, and Turkey.

Under the terms of the agreement, Myovant will receive an upfront payment of US$50 million, and is eligible to receive commercial launch, sales-based, and other milestones totaling up to US$90.5 million. In addition, Myovant is eligible to receive tiered royalties ranging from the high-teens to mid-twenties on net sales. Myovant will continue to lead the global development of relugolix and provide initial product supply to Accord. Accord will be responsible for certain local clinical development, all commercialization for its territories, and has the option to manufacture relugolix in the future.

The Sidley team was led by Technology and Life Sciences Transactions partners Tom Duley (Picture) and Lauren Grau, with support from associates Longbo Wang, Jean Qiu and Ashleigh Lussenden, Ph.D.; and also included Patrick J. Harrison, Laurenz Bové, and Fiona Shajko (Antitrust/Competition); Jen Fernandez and Justine Fassion (Global Arbitration, Trade and Advocacy); Andreas Balsiger Betts and Maurits Lugard (Food, Drug and Medical Device Regulatory); and Alastair Hopwood and David Smith (Commercial Litigation and Disputes).

The Pinsent Masons transactions team was led by Life Sciences Transactions partner Gina Bicknell, with primary support from solicitor Kiah York and legal director Mario Subramaniam.

Involved fees earner: Gina Bicknell – Pinsent Masons; Mario Subramaniam – Pinsent Masons; Kiah York – Pinsent Masons; Andreas Balsiger Betts – Sidley Austin LLP; Laurenz Bové – Sidley Austin LLP; Thomas Duley – Sidley Austin LLP; Justine Fassion – Sidley Austin LLP; Jen Fernandez – Sidley Austin LLP; Lauren Grau – Sidley Austin LLP; Patrick Harrison – Sidley Austin LLP; Alastair Hopwood – Sidley Austin LLP; Maurits Lugard – Sidley Austin LLP; Ashleigh Lussenden – Sidley Austin LLP; Jean Qiu – Sidley Austin LLP; Fiona Shajko – Sidley Austin LLP; David Smith – Sidley Austin LLP; Longbo Wang – Sidley Austin LLP;

Law Firms: Pinsent Masons; Sidley Austin LLP;

Clients: Accord Healthcare Limited ; Myovant Sciences Ltd.;

Martina Bellini

Author: Martina Bellini